Researchers are reporting two promising approaches to counteract malaria's growing drug resistance. Switzerland-based ...

Promising results from a new malaria drug offer hope against emerging drug resistance in Africa. In a clinical trial, ...

Hundreds of malaria patients enrolled in a phase 3 clinical trial in Gabon, West Africa, were successfully treated with a one ...

The drug, known as GanLum, is made by Swiss pharmaceutical giant Novartis. In a late-stage trial, it worked about as well as ...

Scientists have created the first new anti- malaria drug in a quarter of a century to combat resistance to existing ...

In 2022, the WHO hailed Novartis’ GanLum as the most promising non-artemisinin-based combination. The Swiss drugmaker ...

For many Gabonese, malaria remains a constant struggle. Libreville resident Julicia Nfono says the disease keeps coming back ...

Novartis' GanLum met key Phase 3 goals, showing strong efficacy and safety in malaria patients, including against resistant ...

The best drug to fight malaria is facing increased resistance from the parasites it fights. Now there's an alternative in the pipeline and it looks promising.

Phase III trial for KLU156 (ganaplacide/lumefantrine, or GanLum), meets primary endpoint of non-inferiority to standard of care Coartem® (artemether-lumefantrine) Demonstrates PCR-corrected cure rate ...

Hundreds of malaria patients participating in a Phase 3 clinical trial in Gabon in West Africa were cured via a single dose ...